Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 29 of 5804
-
Immune cell boost may keep leukemia at bay after transplant
Disease control Not yet recruitingThe study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML patients.
Phase: PHASE2 • Sponsor: Antonio Pierini • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a tiny dose of a blood thinner cut stroke risk in seniors?
Prevention Not yet recruitingThe overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to help prevent recurrent strokes. However, an antipl…
Phase: PHASE3 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
New hope for tough breast cancer: immune booster after chemo may keep cancer away
Disease control Not yet recruitingThe phase III, multicenter, pragmatic PLANET trial aims to evaluate the benefit and safety of pembrolizumab as an addition to standard of care adjuvant treatment (capecitabine or olaparib) in triple negative breast cancer (TNBC) patients with residual disease (non-pCR) after neoa…
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New 6-Month TB drug cocktail could replace Year-Long ordeal
Disease control Not yet recruitingThe FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional regimen in a French historical cohort of MDR-TB pa…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for aggressive lung cancer: drug duo takes on chemo in major trial
Disease control Not yet recruitingThis trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with tislelizumab in first-line patients with extensive-stage smal…
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
AI reads ECGs to catch deadly aortic tear in minutes
Diagnosis Not yet recruitingThe goal of this prospective multicenter observational study is to learn whether an artificial intelligence model based on electrocardiograms (ECGs) can help diagnose acute type A aortic dissection (TAAD) in adults who come to the emergency department with chest pain or related s…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:09 UTC
-
New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
Disease control Recruiting nowExtranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patie…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Gene therapy offers hope for rare blood disorder
Disease control TerminatedThis is an open-label Phase II trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).
Phase: PHASE2 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene test may spare young breast cancer patients from chemo
Disease control Not yet recruitingRationale: Around 70 to 80% of breast cancers are so-called "hormone-dependent" (HR+)/HER2-. For more than 50 years, studies have shown that chemotherapy and optimised hormonal treatments (hormone therapy), including a drug associated with ovarian suppression (OFS), improve surv…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Donor cells take on tough leukemia in new trial
Disease control Not yet recruitingThis phase 1/2 study is testing a new treatment for acute myeloid leukemia (AML) that has come back or has not responded to other treatments. The treatment uses specially modified immune cells (called CD33 CAR-NK cells) from a healthy, unrelated donor to attack the cancer. The f…
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New dual heart pump offers hope for patients with End-Stage heart failure
Disease control Not yet recruitingAdvanced heart failure is a life-threatening condition characterized by the inability of one or both ventricles to maintain adequate blood circulation. In such cases, medical treatments often prove ineffective, necessitating advanced treatment. Heart transplantation is the standa…
Phase: NA • Sponsor: Shenzhen Core Medical Technology CO.,LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
HIV cure hope: three old drugs aim to flush out and destroy hidden virus
Disease control Not yet recruitingThe PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger…
Phase: PHASE1, PHASE2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a pill replace chemo for some breast cancer patients?
Disease control Not yet recruitingThis study is a Phase III non-inferiority trial targeting a specific subset of early breast cancer patients: those with HR-positive/HER2-negative, node-negative small tumors (typically ≤2cm) but who exhibit high-risk features for recurrence (such as high histological grade, high …
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Shingles shot may shield brain: 33,000 seniors test dementia link
Prevention Recruiting nowThe purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine …
Phase: PHASE4 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
New cocktail of drugs takes on tough pancreatic cancer
Disease control Not yet recruitingThis is a phase III, multi-center study to evaluate the efficacy and safety of chiauranib plus plus toripalimab, albumin-paclitaxel and gemcitabine as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma. The study includes two period: Run-in period and…
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New immunotherapy combo aims to extend life in Tough-to-Treat colorectal cancer
Disease control TerminatedThis study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other important questions include: Is their quality of life …
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Stomach cancer prevention breakthrough? 4,800-Person trial targets High-Risk bacteria
Prevention Not yet recruitingThis study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high risk for gastric cancer. Moreover, the implementation…
Phase: NA • Sponsor: Fudan University • Aim: Prevention
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to crush Hard-to-Treat leukemia
Disease control Recruiting nowThis phase II trial tests the effect of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) with or without rituximab plus ponatinib in treating patients newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leu…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for advanced cervical cancer: experimental drug SHR-A2102 enters phase 3 trial
Disease control Recruiting nowThe main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo shows promise against childhood cancer
Disease control Recruiting nowNeuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease t…
Phase: PHASE2, PHASE3 • Sponsor: Renaissance Pharma Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC